Thus, our findings clearly show that GSK-3β positively regulates c-FLIPL levels in HCC, supporting the concept that GSK-3β acts as a tumor promoter by enhancing c-FLIPL expression in HCC. The gene discussed is GSK3B; the disease is hepatocellular carcinoma.